Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of EP395 in Patients With Chronic Obstructive Pulmonary Disease (COPD)

NCT05572333 is registered in ClinicalTrials.gov with EpiEndo Pharmaceuticals as lead sponsor.

NCT NCT05572333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05572333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised, Double-blind, Placebo-controlled Study to Investigate the Safety and Tolerability of EP395 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lead sponsor
EpiEndo Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
November 22, 2022
Completion date
November 24, 2023
Enrollment
61 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive pulmonary disease, copd